发明名称 |
ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS |
摘要 |
The present invention relates to a pharmaceutical composition comprising propiverine, trospium or glycopyrrolate; and a non-anticholinergic antiemetic agent. It is also related to a pharmaceutical composition comprising a high dose of solifenacin or a pharmaceutically acceptable salts thereof; and a non-anticholinergic antiemetic agent. Pharmaceutical compositions containing high dose of nsPAChA for use for increasing the AChEI blood concentrations and for combating neurodegeneration are also described. The invention also relates to a method for inducing neuroprotection and combating neurodegeneration in a patient suffering from Alzheimer type dementia as well as to a method for increasing the blood levels of an acetyl choline esterase inhibitor (AChEI) in a human subject treated with an AChEI dose. |
申请公布号 |
US2017087142(A1) |
申请公布日期 |
2017.03.30 |
申请号 |
US201615377344 |
申请日期 |
2016.12.13 |
申请人 |
Chase Pharmaceuticals Corporation |
发明人 |
CLARENCE-SMITH Kathleen E.;CHASE Thomas N. |
分类号 |
A61K31/46;A61K31/40;A61K31/454;A61K31/439;A61K31/166;A61K31/325;A61K31/4465;A61K31/4178 |
主分类号 |
A61K31/46 |
代理机构 |
|
代理人 |
|
主权项 |
1. A pharmaceutical composition comprising a nsPAChA selected from the group consisting of propiverine and pharmaceutically acceptable salts thereof, in an amount which is equivalent to from 15 mg to 120 mg of propiverine hydrochloride; trospium pharmaceutically acceptable salts, in an amount which is equivalent to from 20 mg to 480 mg of trospium chloride; and glycopyrrolium pharmaceutically acceptable salts, in an amount which is equivalent to from 2 mg to 16 mg of glycopyrronium bromide; and (b) a non-anticholinergic antiemetic agent (naAEA); in admixture with a pharmaceutical carrier. |
地址 |
Washington DC US |